Paramount Group, Inc.
—- Market cap
- —
- Debt
- +$3.86B
- Cash
- −$375.06M
Complete market value, debt and cash evidence is required for enterprise value.
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
FY 2025 · Mkt capMarket cap $450.22M · View financials
Decision snapshot: PGRE stock price vs ARCT: inconclusive — current versus $18.73 implied using P/S multiple.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at ARCT's multiple
Implied fair value · at PGRE's multiple
Needs PGRE P/S.
Snapshot Sep 4, 4:00 PM ET
Metric by metric
Where each company leads, and how wide the gap is.
Growth edge
Pricing power
Operating leverage
Lower is better
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: PGRE FY 2024 (ended Dec 31, 2024) · ARCT FY 2025 (ended Dec 31, 2025). Fiscal years are not aligned.
Trendline
Ten fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Complete market value, debt and cash evidence is required for enterprise value.
Capital structure 90% equity / 10% debt · EV / Revenue 3.31x
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
PARAMOUNT GROUP, INC. · implied price per share
Five annual free-cash-flow observations are required for the filing-backed baseline.
ARCTURUS THERAPEUTICS HOLDINGS INC. · implied price per share
Latest annual free cash flow must be positive to qualify the filing-backed baseline.
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Debt / equity
Total debt against shareholders' equity
1.23x
0.24x
Net debt / EBITDA
Leverage against operating earnings
28.53x
2.72x
Cash and equivalents
Liquid reserves on the balance sheet
$375.06M
$230.91M
Total debt
Interest-bearing obligations outstanding
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
BXP, Inc.
PGRE vs BXP
SL GREEN REALTY CORP
PGRE vs SLG
VORNADO REALTY TRUST
PGRE vs VNO
KILROY REALTY CORP
PGRE vs KRC
ALEXANDRIA REAL ESTATE EQUITIES, INC.
PGRE vs ARE
Moderna, Inc.
PGRE vs MRNA
BioNTech SE
PGRE vs BNTX
ALNYLAM PHARMACEUTICALS, INC.
PGRE vs ALNY
Sarepta Therapeutics, Inc.
PGRE vs SRPT
Intellia Therapeutics, Inc.
PGRE vs NTLA
$3.86B
$52.00M
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
The deterministic comparison remains available. Sign in when you want an on-demand narrative synthesis of the same data.